Rigel Pharmaceuticals | RIGL - Операционные расходы





Операционные расходы Изменить Дата
Agenus USD 19.81M 293.94M 2025-12
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
Eli Lilly USD 10.02B 285M 2026-03
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Intrexon USD 61.56M 26.1M 2024-06
Ionis Pharmaceuticals USD 364M 54M 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
MacroGenics USD 53.32M 13.68M 2025-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Veracyte USD 116M 7.24M 2025-12